Market Overview

Clovis Shares Reiterated As A Sell Following 10% Rally

Share:
Related CLVS
Tesaro Gets Approval For Zejula, Expect U.S. Launch Late April
Tesaro Announces Expanded Development Program For Cancer Drug Niraparib, Stock Spikes Higher
Moody Aldrich Partners Llc Buys Clovis Oncology, Visteon, Portland General Electric Co, Sells ... (GuruFocus)

AstraZeneca plc (ADR) (NYSE: AZN) on Tuesday presented positive Lynparza results in ovarian cancer maintenance. This raises competitive risks for Clovis Oncology Inc’s (NASDAQ: CLVS) Rubraca, which is currently in the phase III ARIEL3 maintenance study, Chardan Capital Markets’ Madhu Kumar said in a report.

Madhu reiterated a Sell rating for Clovis, with a price target of $36.

Increased Competition

Clovis is expected to present top-line results from Rubraca’s phase III ARIEL3 maintenance study in mid-2017.

“While we understand that success for a second PARPi in the setting of ovarian cancer maintenance therapy arguably further de-risks PARPi as a class in the indication, this de-risking needs to be balanced by the competitive pressures generated by multiple effective PARPis in the ovarian cancer space,” Madhu wrote.

Related Link: Wall Street's M&A Chatter From March 10-12

Moreover, positive results for competitors in the second-line maintenance setting exerts pressure on Rubraca's approved indication of third line or later therapy. The analyst added that the positive SOLO-2 result presented by AstraZeneca “raises the possible risk” of ARIEL3 failing in an absolute or relative sense.

Although Rubraca is being tested for another major indication, that of metastatic castrate-resistant prostate cancer, there are several PARPi competitors in development in combination with AR [androgen receptor] inhibitors, Madhu noted.

Latest Ratings for CLVS

DateFirmActionFromTo
Feb 2017Chardan CapitalDowngradesNeutralSell
Jan 2017Bank of AmericaInitiates Coverage OnBuy
Jan 2017PiperJaffrayUpgradesNeutralOverweight

View More Analyst Ratings for CLVS
View the Latest Analyst Ratings

Posted-In: Chardan Capital Markets Madhu Kumar RubracaAnalyst Color Short Ideas Reiteration Analyst Ratings Trading Ideas

 

Related Articles (AZN + CLVS)

View Comments and Join the Discussion!